

Date: 14th September, 2017

To,
Listing Compliance
BSE Ltd.
P J Towers, Dalal Street,
Mumbai - 400001

Script Code: 540359

Sub.: Discrepancies in Financial Result of the Company for the quarter ended 30th June, 2017

Dear Sir,

This is with reference to your mail dated 12th September, 2017, regarding abovementioned subject, please find attached documents for the same:

1. Revised standalone unaudited financial results for quarter ended 30th June, 2017 as per IND-AS Format in PDF file.
2. Reconciliation table for profit/loss.

We request you to kindly take the above information on record.

Yours faithfully.

For, **PARMAX PHARMA LIMITED**

Alkesh R. Gosalia

Alkesh R. Gosalia
Director
DIN: 01130615



Statement of Standalone Unaudited Results for the Quarter ended 30.06.2017

(in Rs.)

Sr. No.	Particulars	Quarter Ended (30.06.2017)	Preceding Quarter ended (31.03.17)	Quarter Ended (30.06.2016)	Previous year ended (31.03.2017)
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
	(Refer Notes Below)				
1	Income from Operations				
	(a) Revenue from operations	26061713	-	-	-
	(b) Other income	200880	150000	150000	600000
	Total income from operations (net) (a+b)	26262593	150000	150000	600000
2	Expenses				
	(a) Cost of materials consumed	24823650	-	-	-
	(b) Purchase of stock-in-trade	-	-	-	-
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-8477631	-	-	-
	(d) Employee benefits expense	5090282	-	-	-
	(e) Finance Costs	-	-	-	-
	(f) Depreciation and amortisation expense	2487000	-	-	-
	(g) Other expenses	4430804	115444	108960	548787
	Total expenses	28354105	115444	108960	548787
3	Profit/(Loss) from operations before exceptional items and tax (1-2)	-2091512	34556	41040	51213
4	Exceptional Items	-	-	-	-
5	Profit/ (Loss) before tax (3-4)	-2091512	34556	41040	51213
6	Tax expense:				
	(1) Current tax	-	-	-	130000
	(2) Deferred tax	-	-	-	-
7	Net Profit / (Loss) for the period from continuing operations (5-6)	-2091512	34556	41040	-78787
8	Profit/(loss) from discontinuing operations	-	-	-	-
9	Tax expense of discontinuing operations	-	-	-	-
10	Profit/(loss) from Discontinuing operations (after tax) (8-9)	-	-	-	-



Statement of Standalone Unaudited Results for the Quarter ended 30.06.2017

(in Rs.)					
Sr. No.	Particulars	Quarter Ended (30.06.2017)	Preceding Quarter ended	Quarter Ended (30.06.2016)	Previous year ended
	(Refer Notes Below)	(Unaudited)	(Audited)	(Unaudited)	(Audited)
11	Profit (Loss) for the period (7+10)	-2091512	34556	41040	-78787
12	Other Comprehensive Income	-	-	-	-
13	Total Comprehensive Income for the period (11+12) Comprising Profit (Loss) and Other comprehensive Income for the period)	-2091512	34,556.00	41,040.00	-78787
14	Paid-up equity share capital (Face Value Rs 10)	37413000	37413000	37413000	37413000
15	Earnings per share (for continuing operation) (of Rs. <u>10</u> /- each) (not annualised):				
	(a) Basic	-0.56	-	-	-
	(b) Diluted	-	-	-	-

Notes:

- Statement of unaudited financial results of the company rectified for the Quarter ended 30th June, 2017, in the prescribed format under Schedule III of Companies Act, 2013
- Figures have been regrouped wherever necessary.
- The above unaudited financial results have been reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on 12.08.2017.
- The Statutory Auditors have carried out a Limited Review of the Unaudited standalone results of the quarter ended 30th June, 2017
- The Company is operating in single (pharmaceutical) segment, so above results are for single segment only.
- The Statements doesnot include Ind AS compliant result for the preceding quarter and previous year ended 31st March, 2017 as the same are not mandatory as per SEBI's Circular dated 5th July, 2016
- The figures stated above for quarter ending 30th June, 2016 are as per Ind AS and in complete reconciliation with previously applicable GAAP. No difference has been observed between the same. For reference reconciliation table is provided below.

Reconciliation of Net Profit as previously reported under Indian GAAP to Ind-AS for the Quarter ended 30th June, 2016 is as under:

Particulars	Quarter ended 30th June, 2016
Net Profit/Loss as per previous GAAP (IND GAAP)	41040
Adjustments	NIL
Net Profit/Loss as per IND AS	41040

FOR, PARMAX PHARMA LIMITED


Alkesh Gosalia
 Director

 Place Hadamtala (Rajkot)
 Date 12.08.2017

BHARAT A. SHAH

B.Com. F.C.A. (DISA)

B. A. SHAH ASSOCIATES

Chartered Accountants

209 Sapphire, 2nd Floor, 21/25 – B, New Jagnath Plot, Rajkot. – 360 001. Ph.: 0281 - 2468261

The Board of Directors

Parmax Pharma Ltd.

Plot No. 20, Survey No. 52,

Rajkot-Gondal National Highway No 27,

Hadamta,

Tal. Kotada Sangani,

Dist. Rajkot – 360311.

**Report on Limited Review of Unaudited Financial
Result of the Company for the quarter ended on 30th June 2017.**

We have reviewed the accompanying statement of unaudited financial results of **Parmax Pharma Ltd.** for the period ended 30th June 2017. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, *Engagements to Review Financial Statements* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Rajkot

Date: 12.08.2017



B. A. SHAH ASSOCIATES

Chartered Accountant

FRN No. 109493W

Bharat A Shah

BHARAT A. SHAH

Proprietor

Mem. No. 034222